颅内生殖细胞肿瘤的药物治疗  

Drug therapy for intracranial germ cell tumor

作　　者：刘宛榕 赵林[1] LIU Wanrong;ZHAO Lin(Department of Oncology,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing 100730,China)

机构地区：[1]中国医学科学院、北京协和医学院、北京协和医院、肿瘤内科,北京100730

出　　处：《基础医学与临床》2024年第10期1350-1356,共7页Basic and Clinical Medicine

基　　金：北京协和医院中央高水平医院临床科研专项重大攻关计划(2022-PUMCH-D-002)。

摘　　要：颅内生殖细胞肿瘤(IGCT)为一种罕见的脑肿瘤,男性青少年患者最为常见。组织学上可分为生殖细胞瘤、成熟畸胎瘤、未成熟畸胎瘤、伴体细胞型恶性的畸胎瘤(teratoma with somatic-type malignancy)、胚胎癌、卵黄囊瘤、绒毛膜癌和混合型颅内生殖细胞肿瘤。由于传统的大剂量放疗可导致包括神经认知障碍及激素分泌障碍等各种长期不良反应,影响生活质量,故药物治疗的地位逐渐提高。药物选择方面,化疗仍为目前最常用的治疗手段,近年来随着靶向治疗及免疫治疗的发展,各种新型药物亦逐渐走进人们的视野。Intracranial germ cell tumor(IGCT)is an uncommon brain tumor,which is mostly found in male adolescents.The histology of IGCT can be divided into germinoma,mature teratoma,immature teratoma,teratoma with somatic-type malignancy,embryonic carcinoma,yolk sac tumor,choriocarcinoma and mixed intracranial germ cell tumor.Since classic high-dose radiotherapy can lead to a variety of long-term adverse effects including neurocognitive disorders and hormone secretion disorders,affecting the quality of life,chemotherapy with anti-tumor drugs is gradually increasing and clinicians have faced to more choices in the field of drug selection.

关 键 词：颅内生殖细胞肿瘤 化疗 靶向治疗 免疫治疗 

分 类 号：R45[医药卫生—治疗学]